Several mTOR and PI3K inhibitors or mTOR/PI3K dual inhibitors are in early phase clinical studies or already approved for therapy.60, 61 But for a subset of breast cancer patients that would show an ERα-mediated ‘autophagy-footprint' that is comparable to our results, these drugs would not fulfill their autophagy reducing action. This evidence concerns the gene ESR1 and breast cancer.